Nxera Pharma (SOLTF) Stock Price, News & Analysis

Company Overview

Nxera Pharma Co., Ltd., formerly known as Sosei Group Corporation, is a biopharmaceutical company focused on the discovery and development of medicines targeting G protein-coupled receptors (GPCRs). The company combines structure-based drug design, computational technologies and translational research to identify potential treatments for diseases with significant unmet medical needs.

Nxera’s activities include proprietary drug discovery, preclinical and clinical development, and collaborations with pharmaceutical and biotechnology companies. Its research programs have included therapies for conditions in areas such as neuroscience, immunology, inflammation, metabolic disease and other chronic disorders. The company also licenses or partners its drug candidates and discovery technologies to industry collaborators, while advancing selected programs internally.

Headquartered in Japan, Nxera Pharma has an international research and development presence, including operations in the United Kingdom through its Cambridge-based organization. The company was established as Sosei Group and adopted the Nxera Pharma name as part of a broader strategy to build a global, technology-driven biopharmaceutical business. Chris Viehbacher serves as the company’s chief executive officer.

Key Stats

• Today's Range: $7.82 to $7.82
• 50-Day Range: $5.01 to $8.35
• 52-Week Range: $4.90 to $8.35
• Volume: N/A
• Average Volume: 2,448 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/10/2026
• Next Earnings (Estimated): 10/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:SOLTF
• CIK: N/A
• Web: www.sosei.com
• Phone: (135) 210-3290
• Fax: N/A
• Employees: 360
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A